Back

Different definitions of left bundle branch block (LBBB) and survival benefit after cardiac resychronization therapy (CRT)

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: ePosters in device therapy (2) Cardiac Resynchronisation Therapy (CRT) HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Athanasios Saplaouras

Onassis Cardiac Surgery Center, Athens (Greece)

5 More presentations in this session

Presentation thumbnail
Implanted loop recorders in left ventricular assist devices patients; is there a rational?
Doctor M. Wanees Ahmed El Husseny (Aswan, EG)
Abstract Slides Video
Presentation thumbnail
Implantable loop recorder in suspected bradycardic syncope: what predicts pacemaker implantation?
Doctor J. Gouveia Fiuza (Viseu, PT)
Abstract Slides Video
Presentation thumbnail
A simplified risk score for pacemaker implantation in patients undergoing ILR monitoring for bradycardic syncope: the PREDICT-PPM score
Doctor J. Gouveia Fiuza (Viseu, PT)
Abstract Slides Video
Presentation thumbnail
Patient satisfaction with CIED remote monitoring
Mr G. Vilmanyi (Pecs, HU)
Abstract Slides Video
Presentation thumbnail
The prognostic impact of non-progression in cardiac resynchroniation therapy
Doctor M. Bernardo (Vila Real, PT)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in device therapy (2)

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Impact of left bundle branch block morphology in predicting response to left bundle branch area pacing for cardiac resynchronization therapy
thumbnail
Congress Presentation
Different left bundle branch block morphologies and response to CRT: a cohort study
thumbnail
Congress Presentation
Strauss criteria for left bundle branch block in cardiac resynchronization therapy: improved response with lower ventricular arrhythmic burden.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources